Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

(2010) Hideho Okada et al.   JOURNAL OF CLINICAL ONCOLOGY

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients

(2009) Amy B Heimberger et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma

(2008) Michael J. Ciesielski et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients

(2008) C. J. Wheeler et al.   CANCER RESEARCH

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy

(2007) David G. Walker et al.   JOURNAL OF CLINICAL NEUROSCIENCE